Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Drugs Made In America Acquisition Corp.

NASDAQ: DMAA · Real Estate & Construction · 2 alerts · CIK 2028614

Share price
$10.90Close, Nov 17
Market cap
$265M
Shares outstanding
24.28MLatest SEC cover page
Sector
Real Estate & Construction
Industry
Blank ChecksSIC 6770

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Drugs Made In America Acquisition Corp. filings on SEC EDGAR ↗

5:27 PM ET 8-K
M&A Deal

Drugs Made In America Acquisition Signs $1.71B M&A Deal with Power Analytics Global Corp

Drugs Made In America Acquisition Corp. entered into an amendment to its merger agreement with Power Analytics Global Corp (PAGC) to establish a standalone closing valuation of $1.71 billion. This valuation applies if PAGC's acquisition of APQC Inc is not completed by November 1, 2026, down from the original $2.85 billion valuation that included the APQC assets. The merger consideration will be paid entirely in shares at the closing with no earnout provisions.

Value
$1.71B
Counterparty
Power Analytics Global Corp
4:35 PM ET 8-K
M&A Deal

Drugs Made In America Acquisition M&A Deal Update

Drugs Made In America Acquisition Corp., a Special Purpose Acquisition Company (SPAC), has entered into a material definitive agreement, which typically signifies a definitive merger agreement or business combination with a target company. As a SPAC, this filing represents a major strategic milestone toward completing its initial business combination.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.